AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31319165 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall trajectories
Number of subjects: 1897
Study 28478975 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 0.8 mg/kg
Number of subjects: 114
Study 28478975 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate
Number of subjects: 114
Study 28478975 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 0.4 mg/kg
Number of subjects: 114
Study 26021185 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider communication skills training based on motivational interviewing principles
Number of subjects: 26
Study 26021185 — intervention group
Group type: COMPARATOR
Intervention: Control group (providers who did not receive training)
Number of subjects: 26
Study 23439345 — intervention group
Group type: EXPERIMENTAL
Intervention: Sports drinks (SPDs)
Number of subjects: 8
Study 21632652 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training (60 trials of reaching for fast-moving virtual balls with the dominant hand)
Number of subjects: 33
Study 21632652 — intervention group
Group type: COMPARATOR
Intervention: Control group (60 practice trials turning pegs with their non-dominant hand)
Number of subjects: 33
Study 18050378 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 18050378 — intervention group
Group type: COMPARATOR
Intervention: Control treatments
Number of subjects: 0
Study 16760864 — intervention group
Group type: EXPERIMENTAL
Intervention: Balloon-expandable, radially reinforced ePTFE endograft uplining after remote endarterectomy
Number of subjects: 92
Study 14672962 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate (CHO) ingestion (10 ml x kg(‐1) x h(‐1) CHO (6%))
Number of subjects: 30
Study 14672962 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla) ingestion
Number of subjects: 30
Study 14672962 — intervention group
Group type: COMPARATOR
Intervention: Muscle glycogen content
Number of subjects: 30
Study 14672962 — intervention group
Group type: COMPARATOR
Intervention: Muscle cytokine mRNA (IL‐1beta, IL‐6, IL‐8, TNF‐alpha)
Number of subjects: 30
Study 11712339 — intervention group
Group type: EXPERIMENTAL
Intervention: Midline approach for combined spinal-epidural anesthesia (CSEA)
Number of subjects: 70
Study 11712339 — intervention group
Group type: COMPARATOR
Intervention: Paramedian approach for combined spinal-epidural anesthesia (CSEA)
Number of subjects: 70
Study 9273036 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg/kg lidocaine applied topically to the muscle after opening the conjunctiva
Number of subjects: 140
Study 9273036 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9%)
Number of subjects: 140
Study 7962904 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-cured resin composite
Number of subjects: 12
Study 7962904 — intervention group
Group type: COMPARATOR
Intervention: Glass polyalkenoate (ionomer) cement
Number of subjects: 12
Study 3591272 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam (0.15 mg/kg)
Number of subjects: 60
Study 3591272 — intervention group
Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg)
Number of subjects: 60
Study 29889137 — intervention group
Group type: EXPERIMENTAL
Intervention: Mebo ointment
Number of subjects: 161
Study 29889137 — intervention group
Group type: COMPARATOR
Intervention: Biafine cream
Number of subjects: 161
Study 29141665 — intervention group
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol (CZP) treatment for 6 months
Number of subjects: 151
Study 29141665 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 151
Study 29141665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with moderate and severe RA
Number of subjects: 151
Study 29141665 — intervention group
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis patients with stable RA
Number of subjects: 151
Study 26411014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract 1 (36 mg of PACs)
Number of subjects: 0
Study 26411014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract 2 (36 mg of PACs)
Number of subjects: 0
Study 26411014 — intervention group
Group type: EXPERIMENTAL
Intervention: Cranberry extract 3 (36 mg of PACs)
Number of subjects: 0
Study 26411014 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24184894 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1 (25%, 50%, 75%, 100% reversal)
Number of subjects: 640
Study 24184894 — intervention group
Group type: COMPARATOR
Intervention: UFH
Number of subjects: 640
Study 24184894 — intervention group
Group type: EXPERIMENTAL
Intervention: REG1
Number of subjects: 640
Study 21381962 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary massage of twining manipulation with one finger (PMTMOF)
Number of subjects: 500
Study 21381962 — intervention group
Group type: COMPARATOR
Intervention: Conventional tuina manipulation (control)
Number of subjects: 500
Study 18513171 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal, centrally coordinated, multisite hand hygiene culture-change program (HHCCP) implemented over 24 months.
Number of subjects: 2379
Study 18513171 — intervention group
Group type: EXPERIMENTAL
Intervention: Statewide roll-out of the same HHCCP over 12 months.
Number of subjects: 2379
Study 16306456 — intervention group
Group type: EXPERIMENTAL
Intervention: Certoparin (3000 U anti-Xa OD)
Number of subjects: 545
Study 16306456 — intervention group
Group type: COMPARATOR
Intervention: UFH (5000 U TID)
Number of subjects: 545
Study 12841798 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion (75 mg/kg)
Number of subjects: 30
Study 12841798 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion (150 mg/kg)
Number of subjects: 30
Study 12841798 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion (300 mg/kg)
Number of subjects: 30
Study 12841798 — intervention group
Group type: EXPERIMENTAL
Intervention: Emulsion (all doses)
Number of subjects: 30
Study 12841798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 10822931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) males over the age of 10 years
Number of subjects: 48
Study 10822931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) males aged 10-18 years
Number of subjects: 48
Study 10822931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) females over the age of 10 years
Number of subjects: 48
Study 10822931 — intervention group
Group type: EXPERIMENTAL
Intervention: Sickle Cell Disease (SCD) subjects under the age of 10 years
Number of subjects: 48
Study 10822931 — intervention group
Group type: COMPARATOR
Intervention: Sickle Cell Disease (SCD) females
Number of subjects: 48
Study 8850404 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabexate mesilate (GM) 2 mg/kg/h in a central venous catheter
Number of subjects: 30
Study 8850404 — intervention group
Group type: COMPARATOR
Intervention: No GM (control group)
Number of subjects: 30
Study 1626799 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergen solution
Number of subjects: 16
Study 1626799 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 16
Study 6203289 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine 0.5 mg X 3 daily for four weeks
Number of subjects: 27
Study 31329184 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive anti-edematous therapy (CAET)
Number of subjects: 60
Study 31329184 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy with a conventional lymphovenous tonic and elastic compression (Control)
Number of subjects: 60
Study 28786423 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib treatment
Number of subjects: 4482
Study 28786423 — intervention group
Group type: EXPERIMENTAL
Intervention: Lapatinib and taxane combination
Number of subjects: 4482
Study 26763145 — intervention group
Group type: EXPERIMENTAL
Intervention: medetomidine (10 μg/kg)
Number of subjects: 8
Study 26763145 — intervention group
Group type: COMPARATOR
Intervention: medetomidine with MK-467 (250 μg/kg)
Number of subjects: 8
Study 24458508 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS (Resistance Training plus supplementation)
Number of subjects: 22
Study 24458508 — intervention group
Group type: EXPERIMENTAL
Intervention: RT (Resistance Training only)
Number of subjects: 22
Study 24458508 — intervention group
Group type: COMPARATOR
Intervention: C (Control group)
Number of subjects: 22
Study 22382727 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational booklet 'Your Back Operation'
Number of subjects: 117
Study 20458123 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture while under anaesthesia
Number of subjects: 20
Study 20458123 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 20
Study 17384453 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan for 6 months
Number of subjects: 48
Study 17384453 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study 16269882 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine 1.5 mg and Atropine 0.5 mg
Number of subjects: 40
Study 16269882 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous resolution (Control group)
Number of subjects: 40
Study 12393766 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 5 mg ml(-1), 3.5 ml (17.5 mg)
Number of subjects: 66
Study 12393766 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 5 mg ml(-1), 3.5 ml (17.5 mg)
Number of subjects: 66
Study 9926189 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 100 micrograms i.a. (group A)
Number of subjects: 48
Study 9926189 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% 50 mg i.a. (group B)
Number of subjects: 48
Study 9926189 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% i.a. and buprenorphine 100 micrograms i.m. (group C)
Number of subjects: 48
Study 9926189 — intervention group
Group type: COMPARATOR
Intervention: NaCl 0.9% i.a. and NaCl 0.9% i.m. (group D)
Number of subjects: 48
Study 7482412 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-desamino-8-D-arginine vasopressin (DDAVP) infusion
Number of subjects: 62
Study 2179398 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclofenil
Number of subjects: 213
Study 2179398 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 213
Study 528086 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative normovolaemic haemodilution with dextran 70
Number of subjects: 57
Study 528086 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving 500 ml dextran 70 during operation and again on the second postoperative day
Number of subjects: 57
Study 30415629 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (cholecalciferol) at a dose of 2000 IU per day
Number of subjects: 25871
Study 30415629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25871
Study 29995008 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally Invasive Ponto Surgery (MIPS)
Number of subjects: 64
Study 29995008 — intervention group
Group type: COMPARATOR
Intervention: Linear incision technique with soft-tissue preservation (control)
Number of subjects: 64
Study 27769851 — intervention group
Group type: EXPERIMENTAL
Intervention: Active CPAP
Number of subjects: 4
Study 27769851 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 4
Study 25082741 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proCNP levels
Number of subjects: 567
Study 21833551 — intervention group
Group type: EXPERIMENTAL
Intervention: L: -carnitine supplementation and protein-restricted diet
Number of subjects: 0
Study 21833551 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated patients)
Number of subjects: 0
Study 19444973 — intervention group
Group type: EXPERIMENTAL
Intervention: Winter swimming in ice-cold water (WS) for 20 seconds, three times a week for 12 weeks
Number of subjects: 12
Study 19444973 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole body cryotherapy (WBC) for 2 minutes, three times a week for 12 weeks
Number of subjects: 12
Study 17606725 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib (single agent)
Number of subjects: 444
Study 17606725 — intervention group
Group type: EXPERIMENTAL
Intervention: Erlotinib plus gemcitabine
Number of subjects: 444
Study 14674933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 71
Study 14674933 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 71
Study 14674933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study 12189358 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release flecainide acetate (100 mg/day)
Number of subjects: 24
Study 12189358 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release flecainide acetate (200 mg/day)
Number of subjects: 24
Study 12189358 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled-release flecainide acetate
Number of subjects: 24
Study 12189358 — intervention group
Group type: COMPARATOR
Intervention: Immediate-release flecainide acetate
Number of subjects: 24
Study 12189358 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 24
Study 10426254 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional and colour Doppler sonography
Number of subjects: 1074
Study 10426254 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvaginal sonography
Number of subjects: 1074
Study 10426254 — intervention group
Group type: EXPERIMENTAL
Intervention: Doppler sonography
Number of subjects: 1074
Study 7768664 — intervention group
Group type: EXPERIMENTAL
Intervention: Full polyethylene patellar component
Number of subjects: 203
Study 7768664 — intervention group
Group type: EXPERIMENTAL
Intervention: Metal backed component
Number of subjects: 203
Study 7768664 — intervention group
Group type: COMPARATOR
Intervention: Patellar debridement without resurfacing
Number of subjects: 203
Study 7768664 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 203
Study 1693497 — intervention group
Group type: EXPERIMENTAL
Intervention: Krypton red laser photocoagulation
Number of subjects: 247
Study 678389 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg piretanide/day
Number of subjects: 9
Study 678389 — intervention group
Group type: COMPARATOR
Intervention: 40 mg frusemide/day
Number of subjects: 9
Study 678389 — intervention group
Group type: COMPARATOR
Intervention: 1 mg bumetanide/day
Number of subjects: 9
Study 678389 — intervention group
Group type: EXPERIMENTAL
Intervention: All three diuretics
Number of subjects: 9
Study 678389 — intervention group
Group type: EXPERIMENTAL
Intervention: Piretanide
Number of subjects: 9
Study 31266149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod (10 mg)
Number of subjects: 12
Study 31266149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod (10 mg) with cenerimod (2 mg once daily) at near half steady-state (Day 18)
Number of subjects: 12
Study 31266149 — intervention group
Group type: EXPERIMENTAL
Intervention: Ponesimod (10 mg) with cenerimod (2 mg once daily) at steady-state (Day 37)
Number of subjects: 12
Study 31266149 — intervention group
Group type: EXPERIMENTAL
Intervention: Cenerimod (2 mg once daily)
Number of subjects: 12
Study 31266149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 27728839 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance plus balance training (PRBT) - six months of twice weekly machine-based, moderate to high intensity, supervised training followed by six months of unsupervised follow-up.
Number of subjects: 248
Study 27728839 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control) - six months of usual activities before entering the PRBT and follow-up phases.
Number of subjects: 248
Study 26375464 — intervention group
Group type: EXPERIMENTAL
Intervention: ALVAC-HIV
Number of subjects: 16
Study 26375464 — intervention group
Group type: EXPERIMENTAL
Intervention: Remune
Number of subjects: 16
Study 26375464 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 22580932 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (600,000 IU monthly for 8 weeks)
Number of subjects: 53
Study 22580932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 20535607 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazedoxifene 20 mg
Number of subjects: 487
Study 20535607 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study 19750476 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 ml of 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 26
Study 19750476 — intervention group
Group type: COMPARATOR
Intervention: 10 ml of normal saline solution (placebo)
Number of subjects: 26
Study 15872336 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral estrogen (PE) therapy
Number of subjects: 64
Study 15872336 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen therapy
Number of subjects: 64
Study 15872336 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen therapy (combined)
Number of subjects: 64
Study 10576182 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical vaginal 5-fluorouracil (5-FU) cream (2 g) for 6 months
Number of subjects: 101
Study 10576182 — intervention group
Group type: COMPARATOR
Intervention: Observation after standard treatment for 6 months
Number of subjects: 101
Study 8724022 — intervention group
Group type: EXPERIMENTAL
Intervention: Claversal (1g tid)
Number of subjects: 126
Study 8724022 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 126
Study 1757610 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% halobetasol propionate cream
Number of subjects: 264
Study 1757610 — intervention group
Group type: COMPARATOR
Intervention: 0.05% betamethasone dipropionate cream
Number of subjects: 264
Study 1757610 — intervention group
Group type: COMPARATOR
Intervention: 0.05% clobetasol 17-propionate cream
Number of subjects: 264
Study 6925983 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) + BCG
Number of subjects: 217
Study 6925983 — intervention group
Group type: COMPARATOR
Intervention: 5-fluorouracil (5-FU)
Number of subjects: 217
Study 6925983 — intervention group
Group type: COMPARATOR
Intervention: No further treatment (surgery only)
Number of subjects: 217
Study 31901799 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg once daily)
Number of subjects: 0
Study 31901799 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 30702322 — intervention group
Group type: EXPERIMENTAL
Intervention: Partners for Change Outcome Monitoring System (PCOMS)
Number of subjects: 170
Study 30702322 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 170
Study 29931709 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (MPH) for 12 weeks
Number of subjects: 40
Study 29931709 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF) with 30 sessions
Number of subjects: 40
Study 29931709 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 40
Study 26849812 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma (PRP) injection
Number of subjects: 9
Study 26849812 — intervention group
Group type: COMPARATOR
Intervention: Placebo injection (saline)
Number of subjects: 9
Study 26849812 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohort study (not randomized)
Number of subjects: 9
Study 24947034 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (Premarin)
Number of subjects: 30
Study 24947034 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 30
Study 21981991 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 43
Study 21981991 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 43
Study 20347389 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian
Number of subjects: 18
Study 20347389 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17460697 — intervention group
Group type: EXPERIMENTAL
Intervention: Variant in CDKAL1 gene
Number of subjects: 0
Study 17460697 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygous carriers of the CDKAL1 variant
Number of subjects: 0
Study 17460697 — intervention group
Group type: EXPERIMENTAL
Intervention: Homozygotes
Number of subjects: 0
Study 15574713 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone social support
Number of subjects: 0
Study 15574713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nursing presence
Number of subjects: 0
Study 11928796 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 52
Study 11928796 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical interventions (primary resection or lymphadenectomy)
Number of subjects: 52
Study 9536449 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine 300 mg/day
Number of subjects: 7
Study 9536449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7633556 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol
Number of subjects: 0
Study 7633556 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (IB)
Number of subjects: 0
Study 7633556 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of Salbutamol and Ipratropium bromide
Number of subjects: 0
Study 31017556 — intervention group
Group type: EXPERIMENTAL
Intervention: Chicory seed supplementation (infused 9 g/d)
Number of subjects: 92
Study 31017556 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric supplementation (3 g/d)
Number of subjects: 92
Study 31017556 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric and chicory seed supplementation (3 g/d turmeric + infused 9 g/d chicory seed)
Number of subjects: 92
Study 31017556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 28903959 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein breakfast
Number of subjects: 20
Study 28903959 — intervention group
Group type: COMPARATOR
Intervention: High-carbohydrate breakfast
Number of subjects: 20
Study 28903959 — intervention group
Group type: COMPARATOR
Intervention: High-fat breakfast
Number of subjects: 20